Drug intelligence / Profile preview

Cx611

Development stage: Phase 2
Lead developer: Takeda
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

Cx611 is an allogeneic expanded adipose-derived mesenchymal stem cell (eASC) therapy developed by TiGenix (now a subsidiary of Takeda). It consists of multipotent cells isolated from adipose tissue that possess potent immunomodulatory and anti-inflammatory properties. Cx611 works by inhibiting the proliferation and function of major immune cell populations, including T cells, B cells, and natural killer (NK) cells, while inducing regulatory T cells through both cell-contact mechanisms and paracrine effects. The therapy has been investigated in clinical trials for the treatment of refractory rheumatoid arthritis and severe sepsis secondary to community-acquired bacterial pneumonia (CABP).

Other names: allogeneic expanded adipose-derived stem cellseASCs

Beyond the preview

Go deeper on Cx611.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cx611.

Explore the full profile